Literature DB >> 18551826

Available tools for primary ketoacidosis prevention at diabetes diagnosis in children and adolescents. "The Parma campaign".

Maurizio Vanelli1, Chiara Scarabello, Valentina Fainardi.   

Abstract

Diabetic Ketoacidosis (DKA) is a leading cause of death and disability in children with type 1 diabetes (T1D) and it is generally related to a long duration of misdiagnosed hyperglycaemia-related symptoms. Shortening this latency period could be a winning preventive strategy. It is intuitively easy to achieve this goal when other members with T1D in a family exist, as well as during the follow-up of the relatives of patients with T1D positive for genetic, immunological or metabolic markers. An incidental blood glucose level over 100 mg/dl found in children without history for T1D has been reported as indicative of a progressive beta-cell dysfunction and so it may be recommended for DKA prevention at diabetes diagnosis. More encouraging results have been obtained with a campaign of information promoted in schools and in paediatricians' offices, centred on the earliest symptom of diabetes (nocturnal enuresis in a dry child) as reported by 89% of parents. During 8 years of this campaign, the cumulative frequency of DKA dropped from 78% to 12.5% and its long effects were still observed several years after it was promoted. The Parma campaign obtained a reduction in DKA incidence at diabetes diagnosis never found before. The key-success of this campaign may be attributed to the communication of a valuable and reliable message easy to understand and follow; information toward a large population through school and paediatric consultation; involvement of family paediatricians and Parents' Association; free access to experienced health providers in diabetes diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18551826

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  7 in total

1.  Diabetic ketoacidosis at diagnosis in Austrian children in 1989-2008: a population-based analysis.

Authors:  E Schober; B Rami; T Waldhoer
Journal:  Diabetologia       Date:  2010-03-07       Impact factor: 10.122

2.  Diabetic ketoacidosis at diagnosis of type 1 diabetes mellitus in Malaysian children and adolescents.

Authors:  Jyh Hong; M Y Jalaludin; B Mohamad Adam; M Z Fuziah; L L Wu; R Rasat; H Fatimah; S Premaa; U Ponnudurai; H Jamaiyah
Journal:  Malays Fam Physician       Date:  2015-12-31

3.  Medical expenditures associated with diabetes acute complications in privately insured U.S. youth.

Authors:  Sundar S Shrestha; Ping Zhang; Lawrence Barker; Giuseppina Imperatore
Journal:  Diabetes Care       Date:  2010-09-15       Impact factor: 19.112

4.  Delayed diagnosis and issues with pump usage are the leading causes of diabetic ketoacidosis in children with diabetes living in Newfoundland and Labrador, Canada.

Authors:  Jessica Jackman; Roger Chafe; Daniel Albrechtsons; Robert Porter; Colleen Nugent; Shahzad Waheed; Leigh Anne Newhook
Journal:  BMC Res Notes       Date:  2015-04-16

5.  Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.

Authors:  Fergus J Cameron; Shannon E Scratch; Caroline Nadebaum; Elisabeth A Northam; Ildiko Koves; Juliet Jennings; Kristina Finney; Jeffrey J Neil; R Mark Wellard; Mark Mackay; Terrie E Inder
Journal:  Diabetes Care       Date:  2014-06       Impact factor: 19.112

6.  High Frequency of Diabetic Ketoacidosis in Children with Newly Diagnosed Type 1 Diabetes.

Authors:  Agnieszka Szypowska; Anna Ramotowska; Monika Grzechnik-Gryziak; Wojciech Szypowski; Anna Pasierb; Katarzyna Piechowiak
Journal:  J Diabetes Res       Date:  2015-12-13       Impact factor: 4.011

7.  Alarming Increase of Ketoacidosis Prevalence at Type 1 Diabetes-Onset in Austria-Results From a Nationwide Registry.

Authors:  Katrin Nagl; Thomas Waldhör; Sabine E Hofer; Maria Fritsch; Dagmar Meraner; Christine Prchla; Birgit Rami-Merhar; Elke Fröhlich-Reiterer
Journal:  Front Pediatr       Date:  2022-02-14       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.